baber/WOPTO huggingface dataset:
Patent NZ-584647-A (NZ)
Title: Man-over-board rescue device with a scoop type arrangement including weights for submerging the scoop
Inventor: WRIGHT ROBERT CHARLES
IPC: B63C9/22
Filed: 2008-09-17
Abstract: Disclosed is a man overboard rescue device (10) for use on a boat. The device has a net (12) with means of attaching a first end (34) thereof to a boat and with a second opposed end (66) thereof adapted for attaching to a hoisting means (56). The device further comprises a sinking means (50, 52), a foreguy and an extendable pole, so as to provide a partially submerged scoop for the man overboard.
Patent NZ-585091-A (NZ)
Title: Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation
Inventor: LEE YEONG GEON
IPC: C07D307/87
Filed: 2008-10-31
Abstract: Disclosed is a derivative represented by Formula 1 or a pharmaceutically acceptable salt thereof e.g. 1-{ 3-(dimethylamino)propyl} -1-(4-methoxyphenyl)-1,3-dihydro-5-isobenzofurancarbonitrile wherein, R1 and R2 defined in the specification for treating or preventing premature ejaculation.
Patent NZ-587167-A (NZ)
Title: Method of denaturing whey protein
Inventor: ARASE HIROSHI
IPC: A23J3/08
Filed: 2009-03-03
Abstract: Provided is a method of producing a denatured whey protein which has an improved heat stability without using an additive such as an organic solvent. The method comprises contacting and mixing a whey protein solution with a whey protein solution that is flowing as a thin turbulent flow generated between the space of two concentric cylinders. The whey protein solution in the space is sheared at a shearing speed (shear rate) of 5,000 reciprocal seconds to 25,000 reciprocal seconds at a temperature ranging from 76 to 120 degrees Celsius for 8 minutes to 0.1 seconds.
Patent NZ-587614-A (NZ)
Title: A client assistant process
Inventor: KARTHIKEYAN RAMACHANDRAN
IPC: G06Q10/00
Filed: 2010-08-26
Abstract: A client assistant process and a client assistant computer system are disclosed. The computer system (120) includes a client application (142) of an asset management system having different modes for processing asset tag data associated with assets and an assistant interface (140)for monitoring operating system attributes associated with the client application to determine the mode of the client application, and control transfer of asset tag data to the client application from a radio frequency identifiable (RFID) system (106) based on the determined mode. The assistant interface controls writing of asset tag data to an asset tag of an asset by the radio frequency identification (RFID) system based on the determined mode. The client application can be a circulation client application of a library management system and the correct mode is a returns mode of the client application or the determined mode is an issues mode and the asset tag data written to the tag sets a security parameter to off.
Patent NZ-588737-A (NZ)
Title: Methods of diagnosing, preventing and treating bone mass diseases
Inventor: DUCY PATRICIA F
IPC: A61K38/16
Filed: 2009-03-30
Abstract: Disclosed is the use of a TPH1 inhibitor selected from the group consisting of the following formulae, wherein the substituents are defined in the specification e.g. (S)-2-Amino-3-(4-(4-amino-6-((R)-1-(naphthalen-2-yI)ethylamino)-1,3,5-triazin-2-yl)phenyl)propanoic acid and (S)-ethyl-2-amino-3-(4-(2-amino-6-(4-(fluoromethyl)benzylamino)pyrimidin-4-yl)phenyl)propanoate, (2S)-2-amino-3-(4-(2-amino-6-(2,2,2-trifluoro-1-(3'-fluoro-[1,1'-biphenyl]-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and (2S)-ethyl 2-amino-3-(4-(2-amino-6-(2,2,2-trifluoro-1-(3'-fluoro-[1,1'-biphenyl]-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoate for treating or preventing osteoporosis, osteroporosis pseudoglioma syndrome (OPPG), osteopenia, osteomalacia, renal osteodystrophy, faulty bone formation, faulty bone resorption, Paget's disease, fractures, broken bones, or bone metastasis.
Patent NZ-589017-A (NZ)
Title: Solid pharmaceutical formulation with delayed release
Inventor: KANIKANTI VENKATA-RANGARAO
IPC: A61K9/22
Filed: 2009-04-23
Abstract: Disclosed herein is a solid pharmaceutical preparation with delayed release, comprising: a. at least one pharmaceutically active ingredient, b. from 15 to 40% by weight of polyvinylpyrrolidone and/or polyvinylpyrrolidone derivative, being a copolymer of vinylpyrrolidone and vinyl acetate in the ratio 6:4, the polyvinylpyrrolidone and/ or polyvinylpyrrolidone derivative being a mixture i. of a short-chain polyvinylpyrrolidone or polyvinylpyrrolidone derivative having a K value of from 17 to 30 and ii. of a longer-chain polyvinylpyrrolidone or polyvinylpyrrolidone derivative having a K value above 40, c. at least one filler.
Patent NZ-594098-A (NZ)
Title: Long shelf life milk and milk-related products, and a process and milk processing plant for their manufacture
Inventor: ANDERSEN JOERGEN
IPC: A23C3/00
Filed: 2010-01-27
Abstract: 594098 Disclosed is a method for producing a long shelf life milk or milk-related product, which milk or milk related product contains 0 colony forming units/mL, the method comprising the steps of: a) providing a milk derivative; b) physically separating microorganisms from said milk derivative (such as by bactofugation and microfiltration of said milk derivative), thus obtaining a partly sterilised milk derivative; and c) exposing a first composition comprising said partly sterilised milk derivative to a High Temperature (HT)-treatment (such as by Lenient Steam Injection (LSI)), wherein the first composition is heated to a temperature in the range of 140 - 180 degrees C, kept in that temperature range for a period of at most 200 msec, and then finally cooled.
Patent NZ-594207-A (NZ)
Title: Immediate release composition resistant to abuse by intake of alcohol
Inventor: TYGESEN PETER HOLM
IPC: A61K9/20
Filed: 2010-02-05
Abstract: Disclosed herein is the use of a composition comprising a drug substance, a polyglycol having a molecular weight of from 900 to 17,000 daltons, one or more effervescent agents and optionally one or more disintegrants for the manufacture of a medicament for preventing abuse of said drug substance when the composition is ingested with alcohol.
Patent NZ-605841-A (NZ)
Title: Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
Inventor: GRÜNING NADJA
IPC: C07D491/052
Filed: 2011-08-04
Abstract: Disclosed is a pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6'-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine represented by formula (I) or a physiologically acceptable salt thereof, and a surfactant. The pharmaceutical dosage form is intended for treating pain selected from acute, visceral, neuropathic or chronic pain. Also disclosed is the use of the dosage form for the manufacture of a medicament for the treatment of pain.
Patent NZ-609122-A (NZ)
Title: Socket for a multipole plug-in connection
Inventor: ALEXANDER WYSTRON
IPC: H01R13/46
Filed: 2013-04-05
Abstract: A socket for a multipole plug-in connection, in particular for the electric connection of a motor vehicle trailer to a motor vehicle, comprising a socket housing (3) and a socket cover (4) which is arranged on the socket housing (3) in a pivoting manner, wherein the socket housing (3) provides a plug-in pattern (7) comprising seven contact openings (6) and comprises a base body (9) having a cross section that is circular in at least some sections, wherein six of the contact openings (6) are placed on a common fictive straight line (14).
Patent NZ-613309-A (NZ)
Title: Improved container
Inventor: WALSH PHILIP
IPC: B65D55/02
Filed: 2012-01-26
Abstract: A container 100, comprising a thread 120 arranged around an opening of the container 100 for engaging a corresponding thread 120 of a closure 400, more than four retention members 140 arranged around the opening, each retention member having an end-face for abutting a member on an interior surface of the closure to impede unthreading of the closure. The retention members 140 are arranged such that a tangent to each end face of the retention members 140 intersects a plane 160 bisecting the container 100 at an obtuse angle 171. The retention members 140 are arranged into two first retention members 141 and two groups of retention members 142. The first retention members 141 each have an end-face substantially parallel to the plane 160 bisecting the container 100. A first one of the first retention members 141 and one of the groups 142 is arranged on one side of the plane 160 each in a respective quadrant of the container 100, and the other one of the first retention members 141 and the other one of the groups 142 is arranged on the other side of the plane 160 each in a respective quadrant of the container 100. The teeth of each of the groups 142 have a first inter-tooth spacing, and an inter-tooth spacing between an end-face of the first one of the first retention members 141 and a first retention member of the group 142 on one side of the plane 160 is larger than the first inter-tooth spacing. An inter-tooth spacing between the end-face of the first one of the first retention members 141 and a first retention member of the group 142 on the other side of the plane 160 is larger than the first inter-tooth spacing.
Patent NZ-616035-A (NZ)
Title: Compositions relating to a mutant clostridium difficile toxin and methods thereof
Inventor: SIDHU MANINDER K
IPC: C07K16/12
Filed: 2012-04-20
Abstract: Disclosed is an immunogenic composition comprising a mutant Clostridium difficile toxin A, which comprises a wild-type Clostridium difficile toxin A having (a) a glucosyltransferase domain having at least one amino acid mutation, wherein the mutation is located at any one of amino acid positions 101, 269, 272, 285, 287, 460, 462, 541, or 542, according to the numbering of SEQ ID NO: 1; and (b) a cysteine protease domain having at least one amino acid mutation, wherein the mutation is located at any one of amino acid positions 700, 589, 655, or 543, according to the numbering of SEQ ID NO: 1, relative to the corresponding wild-type Clostridium difficile toxin A; and a diluent. Also disclosed is an immunogenic composition comprising a mutant Clostridium difficile toxin B, which comprises a wild-type Clostridium difficile toxin B having (a) a glucosyltransferase domain having at least one amino acid mutation, wherein the mutation is located at any one of amino acid positions 102, 286, 288, 270, 273, 384, 461, 463, 520, or 543, according to the numbering of SEQ ID NO: 2; and (b) a cysteine protease domain having at least one amino acid mutation, wherein the mutation is located at any one of amino acid positions 698, 653, 587, or 544, according to the numbering of SEQ ID NO: 2, relative to the corresponding wild-type Clostridium difficile 5 toxin B; and a diluent.
Patent NZ-619771-A (NZ)
Title: Hole borer
Inventor: ANGUS PETER ROBSON
IPC: E21B10/44
Filed: 2013-07-22
Abstract: 619771 Disclosed is a hole borer including an elongate sleeve (2), an auger (6) located within the sleeve, and a deployment apparatus (12) which effects rotation of the auger and linear movement of the auger through the sleeve. The auger includes a cutting face (11). The elongate sleeve is formed with a laterally-enlarged flange (13) at the ground engaging end. The sleeve is maintained above the ground surface while the auger is drivable into the ground. The flange provides a means of applying stabilising downward pressure to the periphery of the hole created by the auger, such that the flange prevents ground heave about the periphery of the hole and prevents any spoil surrounding the hole perimeter from falling into the hole during drilling. A method of operating a hole borer is also disclosed.
Patent NZ-625807-A (NZ)
Title: Human anti-b7rp1 neutralizing antibodies
Inventor: HUANG HAICHUN
IPC: G01N33/68
Filed: 2006-07-18
Abstract: Disclosed is an antibody that binds specifically to B7RP1 wherein the antibody, or an antigen-binding or an immunologically functional immunoglobulin fragment thereof, comprises a light chain comprising a CDR1 sequence as set forth in SEQ ID NO: 18 (RASQSVSSYLA) and a light chain comprising a CDR2 sequence as set forth in SEQ ID NO: 19 (DASNRAT), the antibody or the fragment thereof further comprising: (a) a heavy chain CDR1 sequence as set forth in SEQ ID NO: 30 (SYGMH), a heavy chain CDR2 sequence as set forth in SEQ ID NO: 31 (VIWYDGSKKYYADSVEG), a heavy chain CDR3 sequence as set forth in SEQ ID NO: 32 (DLNIMVWGIFDY), and a light chain CDR3 sequence as set forth in SEQ ID NO: 20 (QQRNNWPWT); or (b) a heavy chain CDR1 sequence as set forth in SEQ ID NO: 35 (SYAMH), a heavy chain CDR2 sequence as set forth in SEQ ID NO: 36 (AIGTGGGTYYADSVKG), a heavy chain CDR3 sequence as set forth in SEQ ID NO: 37 (GVPLLWFGEFY), and a light chain CDR3 sequence as set forth in SEQ ID NO: 23 (QQRSNWPALT); wherein the antibody or the fragment thereof inhibits B7RP1 activity.
Patent NZ-627772-A (NZ)
Title: Synthetic apelin mimetics for the treatment of heart failure
Inventor: GOLOSOV ANDREI
IPC: C07K14/47
Filed: 2013-01-25
Abstract: Disclosed is a polypeptide having the following formula I’ (as shown in the abstract figure), wherein: X1 is the N-terminus of the polypeptide and is either absent or is selected from pE, R, Isn, Q, A, K, and 5-amino-valeric acid; X2 is R, A, r, N-Me-R, K, H, hF, hK, F, E or Orn; X3 is P, A, a, p, 4-PhP, K, D, pipecolic acid, or cysteine wherein the side chain of cysteine forms a disulfide bond with the side chain of the cysteine at the X7 position; X4 is R, A, r, N-Me-R, F, E or cysteine wherein the side chain of cysteine forms a disulfide bond with the side chain of the cysteine at the X7 position; X5 is L, Cha, A, D-L, N-Me-L, K, D, 4-PhF or F; X6 and X12 are independently a natural or unnatural amino acid selected from C, c, hC, DhC, K, D, Orn, Dab or E wherein the side chain of X6 and X12 are linked together via a covalent bond forming either a monosulfide (-S-), a disulfide (-S-S-) or an amide bond (NHC(O)- or -C(O)-NH-) or a linkage of Formula -S-CHr C(=Z)-CH2-S-; wherein Z is 0, N-OCH2C(O)-L 1_R1 or N-NH-CH2C(0)-L 1_R1 wherein R1 is a fatty acid derivative and L 1 is a linker containing one or more amino acids and/or one or more -NH-C2_6-alkylene-NH- units; or alternatively X6 is K, X13 is absent and X12 is F or f wherein the C-terminus of X12 form an amide bond with the amino side chain of X6; X7 is H, h, A, N-Me-A, a, Aib, K, Nal, F, P, Dap, N, E or cysteine wherein the side chain of the cysteine forms a disulfide bond with the side chain of the cysteine at position X3 or with the side chain of the cysteine at position X4; X8 is K, k, F, f, A, hF, N-Me-R, E or 4-amino-lsn; X9 is G, N-Me-G, A, D, L, R or Aib; X10 is P, A, p, 4-PhP or pipecolic acid, X11 is M, D-Nle, Nle, N-Me-Nle, M(O), A, F, Y, L, K, 3-PyA or Cha; and X13 is the C-terminus and is absent or is selected from F, f, N-Me-F, Nal, D-Nal, 3-Br-F, (S)P-3-F, I, A, a, K, Dap, Hand E; wherein: Nle is L-norleucine; D-hC is D-homocysteine hC is L-homocysteine; hF is L-homophenylalanine; hK is L-Iysine; Nal is L-naphathaline; Orn is ornithine; Aib is α-aminoisobutyric acid; Dab is (S)-diaminobutyric acid; Dap is (S)-2,3-diaminopropionic acid; M(O) is methionine sulfone; Cha is (S)-β-cyclohexylalanine; 4-amino-lsn is 4-aminopiperidine-4-carboxylic acid; Isn is isonipecotinoyl; pE is L-pyroglutamic acid; 3-PyA is 3-(3-pyridyl)-L-alanine; 4-PhF is 4-Phenyl-L-phenylalanine; wherein the N-terminus and the C-terminus optionally form a ring together with 1, 2, 3 or 4 glycine amino acids; and wherein the amino group in the side chain of K, Orn, Dab, Dap, hK or 4-amino-lsn is optionally linked to a lipophilic group via an amide bond; or an amide, an ester or a salt of the polypeptide; or a polypeptide substantially equivalent thereto.
Patent NZ-628314-A (NZ)
Title: Cd47 antibodies and methods of use thereof
Inventor: DEVERAUX QUINN
IPC: C12P21/08
Filed: 2013-02-06
Abstract: Discloses isolated monoclonal antibodies that bind to CD47, block CD47 from interacting with signal-regulatory-protein alpha (SIRPα) and do not cause a significant level of agglutination of cells after administration. Also discloses the use of the antibodies for treating neoplastic conditions including cancer.
Patent NZ-631064-A (NZ)
Title: Reclosable flexible packages for food products
Inventor: KARUL KADIR
IPC: B65D77/16
Filed: 2013-06-24
Abstract: A reclosable flexible package (10) for storing a food product (30) and a method of manufacture thereof are disclosed. The package (10) includes a flexible film side wall (12), a closed first end (11), a closed second end portion (not shown) that can be separated from the side wall to provide an access opening (19), and a collar (20). The collar (20) can be formed in the side wall or attached to the side wall. The collar is more rigid than adjacent portions of the side wall and is rotatable about the longitudinal axis of the package to twist portions (25) of the side wall and block access to the opening after removal of the second end portion. The collar can be slide towards the first end, after twisting, to frictionally engage the side wall and prevent the twisted portion from unwinding.
Patent NZ-701991-A (NZ)
Title: An advertisement element, a method of creating an advertisement element and a method of capturing advertisement images on an advertisement element
Inventor: SØNDERGAARD CHRISTIAN JOKUM
IPC: G09F19/14
Filed: 2013-07-03
Abstract: An advertisement element (2) having an underside adapted for positioning on a flat surface and an upper side comprising an advertisement surface with advertisement information, wherein the advertisement surface comprises a plurality of protrusions (12), wherein each protrusion (12) comprises a first display surface (14) with graphics applied to the surface, said surface (14) and graphics being oriented towards a first predefined viewpoint (4) and a second display surface with graphics applied to the surface, said surface and graphics being oriented towards a second predefined viewpoint (6), and wherein the advertisement information comprises a first image (8) composed of the combined graphics on the first display surfaces (14) and a second image composed of the combined graphics on the second display surfaces. A method of creating said advertisement element (2) and a method of capturing advertisement images.
Patent NZ-706734-A (NZ)
Title: Pharmaceutical compositions useful for the treatment or control of bacterial infections
Inventor: BHAGWAT SACHIN
IPC: A61P31/00
Filed: 2013-05-13
Abstract: Pharmaceutical compositions useful for the treatment or control of bacterial infections, comprising effective amounts of: (a) at least one beta-lactam antibiotic agent or a pharmaceutically acceptable derivative thereof, (b) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, and (c) mecillinam or a pharmaceutically acceptable derivative thereof, wherein the beta-lactam antibiotic agent is a cephem compound are disclosed.
Patent NZ-708476-A (NZ)
Title: Fluid-entangled laminate webs having hollow projections and a process and apparatus for making the same
Inventor: KIRBY SCOTT S C
IPC: D04H1/495
Filed: 2013-10-30
Abstract: The claimed method for producing fluid-entangled laminate web improves resilience at low basis weight, with the projections not degrading when wound on a roll and put through subsequent converting processes. The present invention is directed to a fluid-entangled laminate web and the process and apparatus for its formation as well as end uses for the fluid-entangled laminate web. The laminate web includes a support layer and a nonwoven projection web having a plurality of projections which are preferably hollow. As a result of the fluid-entangling process, entangling fluid is directed through the support layer and into the projection web which is situated on a fanning surface. The force of the entangling fluid causes the two layers to be joined to one another and the fluid causes a portion of the fibers in the projection web to be forced into openings present in the fanning surface thereby forming the hollow projections. The resultant laminate has a number of uses including, but not limited to, both wet and dry wiping materials, as well as incorporation into various portions of personal care absorbent articles and use in packaging especially food packaging where fluid control is an issue.
Patent NZ-714765-A (NZ)
Title: Anti-c10orf54 antibodies and uses thereof
Inventor: KIM SUN
IPC: A61K39/395
Filed: 2014-06-06
Abstract: The present disclosure relates to antagonistic anti-C10orf54 antibodies 175A, 76E1 and 141A as well as their anti-tumor use. In particular, 175A comprises six CDRs of GYTFSTHWIE, EILPGSGSTSYNEKFKG, WLLYYYAMDY, RSSQSIVHSNGNTYLE, KLSNRFS and FQGSHFPYT. 76E1 comprise six CDRs of GYSFTGYNMN, NIDPYYDYTSYN, STMITPFDY, RSSQSIVHSNGNTYLE, KVSNRFS and FQGSHVPWT. 141A comprise six CDRs of GYTFSRYWIE, EILPGSGSTNYNEKFKG, EEVYDGYPWFGY, RASSSLSYMH, ATSNLAS and QQWSSNPYT.
Patent NZ-718380-A (NZ)
Title: System and method for augmented and virtual reality
Inventor: MILLER SAMUEL A
IPC: G06T19/00
Filed: 2012-10-29
Abstract: A system for enabling two or more users to interact within a virtual world comprising virtual world data comprises a computer network comprising one or more computing devices and a user device. The one or more computing devices comprise memory, processing circuitry, and software stored at least in part in the memory and executable by the processing circuitry to process at least a portion of the virtual world data. The user device has a wearable user display component, wherein the user device is operatively coupled to the computer network. At least a first portion of the virtual world data comprises a virtual object rendered from and representing a physical object local to a first user and the computer network is operable to transmit the first portion of the virtual world data to the user device associated with a second user. The wearable user display component visually displays the virtual object to the second user, such that a virtual representation of the physical object local to the first user is visually presented to the second user at the second user’s location.
Patent NZ-734420-A (NZ)
Title: A device intrinsically designed to resonate, suitable for rf power transfer as well as group including such device and usable for the production of plasma
Inventor: SELMO ANTONIO FRANCO
IPC: H02J50/00
Filed: 2016-01-15
Abstract: The present invention is directed to the field of generation of materials using radio frequency (RF) power and particularly relates to a device, apparatus, method and a group consisting of such device for achieving resonance intrinsically for the generation of materials. The solutions provided by the state of the art have inefficient RF power transfer capabilities due to various reasons such as very low modulus inductive component compared to the parasitic impedance of the RF circuits thereby reducing the power transferred by the RF power supply. Moreover, current RF power supplies are powered mainly by RF sine wave power supplies. The present invention addresses the above problems by providing a device configured to resonate intrinsically to efficiently transfer RF power to a load contained therein e.g. a gas, for the production of materials such as plasma. The device in accordance with the present invention comprises an inductive element, a capacitive element and an electrical wire connection between an RF power amplifier and the device, each of the inductive element and the capacitive element having values such that at resonance, they provide an equivalent impedance substantially of the resistive type, measured at the terminals of the device, making the parasitic impedance upstream of the terminals of the device substantially negligible. Uses of the present invention include generation of materials. Specifically, the present invention may be used to generate plasma from a gas input to the claimed device.